SurvivorNet on MSN
Enhertu significantly cuts recurrence rates for women with high-risk HER2-positive breast cancer — the practice-changing DESTINY-Breast05 trial
DESTINY-Breast05 is a large phase 3 trial in women with HER2-positive early-stage breast cancer who had chemotherapy and ...
A new tool can help physicians determine which patients with localized pancreatic neuroendocrine tumors (PanNETs) have an ...
The Miami Beach keloid specialist outlines why pairing surgical excision with superficial radiation therapy can reduce ...
BOOG 13-08 shows skipping sentinel lymph node biopsy in patients 50+ with early-stage, hormone receptor–positive, ...
5don MSN
Bruno Fernandes and Man United given ‘red zone’ warning as tough talks held behind scenes
The Manchester United captain could face some rare time on the sidelines after suffering a hamstring injury against Aston ...
Platinum-resistant recurrent epithelial ovarian cancer carries a bleak prognosis, with single-agent chemotherapy yielding ...
Final results from the phase 3 CASSANDRA trial presented at the 2025 ASCO Meeting show that the neoadjuvant chemotherapy ...
Radiation has been a staple of breast cancer treatment for decades, but a new study is casting doubt on whether it is ...
Rocket Pharmaceuticals is a Buy, with strong catalysts, undervalued programs, and significant upside. Click here to read my ...
Olema Pharmaceuticals (OLMA) earns a "Strong Buy" rating, driven by advancing palazestrant for 1st-line ER+/HER2- metastatic ...
Adjuvant carboplatin added to standard anthracycline/taxane chemotherapy significantly improves outcomes in early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback